Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L DAVILA

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Transplantation and Cellular Therapy|July 5, 2026
System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced CostShernan G Holtan, Megan M Herr, Kanwal Mallhi, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Gastrointestinal Endoscopy|February 10, 2016
Outcome of EMR as an alternative to surgery in patients with complex colon polypsGottumukkala S Raju, Phillip J Lum, William A Ross, et al.
Frontiers in Immunology|June 6, 2018
VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and RearrangementsScott Christley, Walter Scarborough, Eddie Salinas, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.
The Journal of Clinical Investigation|October 30, 2025
IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapyPayal Goala, Yongliang Zhang, Nolan Beatty, et al.
International Journal of Molecular Sciences|May 7, 2025
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) TherapySepideh Mokhtari, Justin M Asquith, Syeda Saba Kareem, et al.
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
Molecular Therapy. Methods & Clinical Development|September 14, 2018
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository ExperienceKenneth Cornetta, Lisa Duffy, Steven A Feldman, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Transplantation and Cellular Therapy|July 5, 2026
System-Level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated with High 1-Year Survival and Reduced CostShernan G Holtan, Megan M Herr, Kanwal Mallhi, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Gastrointestinal Endoscopy|February 10, 2016
Outcome of EMR as an alternative to surgery in patients with complex colon polypsGottumukkala S Raju, Phillip J Lum, William A Ross, et al.
Frontiers in Immunology|June 6, 2018
VDJServer: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and RearrangementsScott Christley, Walter Scarborough, Eddie Salinas, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.
The Journal of Clinical Investigation|October 30, 2025
IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapyPayal Goala, Yongliang Zhang, Nolan Beatty, et al.
International Journal of Molecular Sciences|May 7, 2025
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) TherapySepideh Mokhtari, Justin M Asquith, Syeda Saba Kareem, et al.
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
Molecular Therapy. Methods & Clinical Development|September 14, 2018
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository ExperienceKenneth Cornetta, Lisa Duffy, Steven A Feldman, et al.
Pageof 10